Avecho Biotechnology Limited announced that it is proceeding to the next phase of its recently announced cannabinoid development program - human clinical trials. This decision is supported by positive results from preliminary in vivo studies which confirmed significantly increased cannabidiol (CBD) bioavailability from oral TPM® cannabidiol formulations in rats. The development program consists of three main components; (i) in vitro testing in simulated gastro-intestinal digestions, (ii) animal studies to assess in vivo bioavailability of candidate formulations, and (iii) subsequent human trials testing the best formulations. Researchers at Bioneer:FARMA, located within the University of Copenhagen, had previously completed the in-vitro testing, demonstrating that formulations containing TPM® significantly increased CBD solubility during gastric and intestinal in vitro digestion. In the subsequent study, single doses of these same formulations were administered to rats using an oral gavage to characterise the CBD absorption profile over 24 hours. The average area-under-the-curve (AUC) of the CBD absorption profile and peak plasma concentration (Cmax) were calculated for each formulation. AUC and Cmax are standard measurements used to characterize drug absorption. For this study, they were used to compare the amount of CBD absorbed between different formulations. CBD absorption from formulations containing TPM® was compared against a commonly prescribed CBD product comprising CBD at 100 mg/ml. Study results: All TPM® formulations produced higher mean AUC and Cmax than the commercial CBD formulation. Increases in AUC produced by TPM® formulations ranged from 4-40 times. Increases in Cmax produced by TPM® formulations ranged from 6-41 times. These increases were statistically significant for the best performing TPM® formulations. Further animal work may be conducted, but the dramatic increases in CBD absorption are already sufficiently compelling to initiate formal human clinical trials. Planning for these studies is already underway, with dosing expected to begin first quarter of 2021.